Evotec OAI in virtual screening agreement with Fujisawa
German drug discovery and development company Evotec OAI has entered into an integrated virtual screening and medicinal chemistry collaboration with Japanese pharmaceutical manufacturer Fujisawa Pharmaceutical Co, to identify, synthesise and optimise compounds that show biological activity against one of Fujisawa's drug targets.
German drug discovery and development company Evotec OAI has entered into an integrated virtual screening and medicinal chemistry collaboration with Japanese pharmaceutical manufacturer Fujisawa Pharmaceutical Co, to identify, synthesise and optimise compounds that show biological activity against one of Fujisawa's drug targets.
Using integrated virtual screening and compound design software/expertise Evotec OAI will mine Fujisawa's chemical databases to identify and synthesise compounds that are predicted to be active against the target. Fujisawa will conduct biological screening of the compounds. In parallel, using Evotec OAI's medicinal chemistry platform, these hits will be further optimised in terms of their potency, selectivity, in vitro ADMET and pharmacokinetic profile for the subsequent progression into a lead optimisation programme.
Evotec OAI will receive fees for services carried out and milestone payments for the successful achievement of predefined scientific results. Financial terms and Fujisawa's drug target were not disclosed.